Japan-Weekly Strategy Report “ Looking Back at the Week Where a Storm Raged Due to Monetary Policies ”

21 Jun 2022

Report type: Weekly Strategy

Looking Back at the Week Where a Storm Raged Due to Monetary Policies

 It was a week where a storm ravaged the Japanese stock market. It was a situation where the storm began from the U.S. Consumer Price Index for May announced on the 10th having an 8.6% increase year-on-year, which was a high growth last since 40 years and 5 months ago.  

 Prior to the U.S. Federal Open Market Committee (FOMC) statement announcement on the 15th, although the probability of a 0.75% interest rate hike was in the 20% range until the 10th in “FedWatch” (forecasted probability of an interest rate hike calculated by the CME Group based on futures market data of the FF rate which is the U.S. policy interest rate), it jumped to the 90% range in the beginning of the week from 13th onwards. Furthermore, the forecasted probability of an additional 0.75% interest rate hike at the FOMC as well which is to be held in late July also rose to the 90% range. First, an ad hoc meeting of the European Central Bank (ECB) Governing Council was held on the 15th. Due to the increase in the yield spread of southern Europe, such as Italy and Germany’s government bonds from the decline in the bond market, as a countermeasure, there were movements to slow down the speed of one-sided monetary tightening, such as by flexibly carrying out reinvestment of assets owned which have been purchased via a quantitative easing policy.   

 Although a large additional rate hike of 0.75% has been decided at the U.S. FOMC on the 15th, due to U.S. FRB Chair Powell’s remark at the conference on “it likely being 0.50% or 0.75% in July the next round, and 0.75% being unusual”, there was a scenario of a temporary lead in buybacks from the emergence of a sense of relief on it not being hawkish to an extent where the market was wary. Up to this point, it was led by an aspect of having expectations that “perhaps a one-sided hawkish trend would loosen a little”.     

 However, on the 16th, the Swiss National Bank central bank raised their existing policy interest rate by 0.5 points from -0.75% to -0.25%, which was deemed a “dovish” example to drive quantitative easing that matched the Bank of Japan. This spurred global monetary tightening and the risk off trend officially resumed after the end of trading in the Tokyo Stock Exchange on the 16th. In response, for the Japanese stock market on the 17th, the Nikkei average also ended up falling under 26,000 points, which was a decline of more than 9% from the high on the 9th last week. 

 With the existence of overseas hedge funds becoming public which have short commitments of Japanese government bond futures that anticipate the likelihood of a policy revision by the Bank of Japan, at the Monetary Policy Meeting for the results announcement on the 17th, it was decided by a majority vote to continue the existing quantitative and qualitative monetary easing policy with long and short-term interest rate control. If the long-term interest rate stabilises at a low level while there is a forecasted acceleration in inflation, there will be an increase in a negative real interest rate (yield after subtracting the expected inflation rate from the nominal interest rate), which is beneficial for investment. If accompanied by a depreciation in the yen, it is expected that it will be even more favourable for stock investment.

 Ahead of Japan’s House of Councillors election’s public announcement on 22/6 and the voting and counting on the 10/7, following the Basic Policy on the plan to execute the “New Form of Capitalism”, there is a need to pay attention on aspects of successive policy announcements that focus on long-term political power after the election, such as movements involving the establishment of the “Cabinet Secretariat infectious disease crisis management agency” and the conclusion of the bill to establish the “children and families agency”.

 

 In the 20/6 issue, we will be covering JP-Holdings (2749), Ship Healthcare Holdings (3360), Toray Industries (3402) and Anycolor (5032).

JP-Holdings, Inc. (2749)              225  yen (17/6 closing price)

Established in Nagoya City in 1993. Carries out the childrearing support business which operates private after-school childcare, children’s centres and after-school childcare and nurseries which have been authorised and approved by municipalities. Gakken Holdings (9470) is their top shareholder at 30% holding.

For FY2022/3 results announced on 12/5, net sales increased by 2.6% to 34.373 billion yen compared to the previous year and operating income increased by 17.1% to 3.344 billion yen. The new establishment of 8 facilities of after-school childcare and children’s centres as well as 3 nurseries (total of 303 childrearing support facilities) contributed to the increase in revenue. Due to a reallocation of personnel and review of their order placing system, etc., SGA ratio fell by 0.16 points.  

For its FY2023/3 plan, net sales is expected to increase by 3.7% to 35.64 billion yen compared to the previous year, operating income to increase by 6.4% to 3.56 billion yen and annual dividend to have a dividend increase by 1.50 yen to 6.00 yen. With efforts to accelerate developments in after-school childcare towards resolving the childcare waiting list via the “new and after-school children comprehensive plan” and childcare arrangements based on the “new childrearing assurance plan” by the government, the bill to establish the “children and families agency” was concluded on 15/6. Prime Minister Kishida also expressed a significant increase in the one-off payment for childbirth in the countermeasures for the declining birth rate.   

Ship Healthcare Holdings, Inc. (3360)           2,350  yen (17/6 closing price)

Established in 1992. In addition to the total pack produce business which carries out comprehensive batch order receipt services in the medical, health, welfare and nursing care fields, they manage the medical supply business, lifecare business and dispensing pharmacy business, etc. 

For FY2022/3 results announced on 10/5, net sales was 514.3 billion yen (497.1 billion yen in the previous year before the application of the accounting standard for revenue recognition) and operating income decreased by 5.9% to 20.5 billion yen. Although 3 businesses which are medical supply, lifecare and dispensing pharmacy contributed to an increase in revenue, the decrease in scale of projects involving the high profit margin total pack produce business affected the profit aspect. 

For its FY2023/3 plan, net sales is expected to increase by 8.9% to 560 billion yen compared to the previous year, operating income to increase by 2.4% to 21 billion yen and annual dividend to have an increase by 1 yen to 42 yen. On the 15th, Prime Minister Kishida expressed the establishment of a “Cabinet Secretariat infectious diseases crisis management agency” in order to reinforce control tower functions involving infectious diseases countermeasures. An overview was established on the bill to revise the Infectious Disease Act, which constitutes authority that enables the government to instruct medical institutions in order to secure hospital beds in the event of an emergency. This will likely benefit the total pack produce business.     

About the author

Phillip Research Team (Japan)

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com